Opportunity Information: Apply for RFA AT 24 004
The NIH-DoD-VA Pain Management Collaboratory (PMC) funding opportunity (RFA AT 24 004) supports phased UG3/UH3 cooperative agreement projects that test real-world, nonpharmacologic approaches to pain management for U.S. veterans, active-duty military personnel, and their families, often in the context of other common co-occurring conditions. The central aim is to run efficient, large-scale pragmatic clinical trials and/or implementation science demonstration projects embedded in health care systems, meaning studies are expected to reflect routine care settings and practical constraints rather than tightly controlled laboratory-style conditions. A clinical trial is required under this announcement, and the focus is specifically on demonstrating how non-drug pain care strategies work in real clinical environments and how they can be adopted, delivered, and sustained at scale.
The UG3/UH3 structure is a two-phase, milestone-driven model. The UG3 phase typically functions as a planning and startup period where investigators finalize protocols, build site readiness, complete key regulatory and operational steps, and demonstrate feasibility benchmarks. If the UG3 milestones are met, the project transitions to the UH3 phase, which is the larger implementation and execution period where the pragmatic trial and/or implementation study is carried out across health system settings. Because this is a cooperative agreement, NIH expects substantial scientific and programmatic involvement during the life of the award, which commonly includes coordinated oversight, collaboration on common methods and standards, and active engagement with the broader collaboratory infrastructure.
A defining feature of this opportunity is that projects must operate within the infrastructure of the NIH-DoD-VA Pain Management Collaboratory. The PMC includes a Coordinating Center designed to provide national leadership and hands-on technical expertise for health care system-focused research. In practical terms, awardees can expect support and coordination around issues that commonly make pragmatic trials difficult: working across multiple health care sites, aligning workflows with clinical operations, dealing with real-world data sources (like electronic health records), standardizing outcomes where appropriate, and managing implementation challenges such as clinician uptake, fidelity, adaptation, and sustainability. The intent is to reduce duplication of effort and increase the odds that results are actionable for large health systems like the VA and DoD.
The scientific scope emphasizes nonpharmacologic pain management and related comorbidities. While the notice summary does not list specific interventions, the framing signals interest in evidence-based, non-drug approaches that can be delivered in routine practice and evaluated at scale. The mention of “other comorbid conditions” reflects how pain in veteran and military populations often intersects with behavioral health, sleep problems, physical function limitations, and other chronic conditions, and it leaves room for projects that either address pain alongside these issues or evaluate integrated care models that better fit patient complexity.
Eligibility is broad and intentionally inclusive of many organization types that can conduct large pragmatic research in health care settings. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; public and private institutions of higher education; federally recognized tribal governments; tribal organizations other than federally recognized governments; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses. The opportunity also explicitly calls out additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, tribal governments other than federally recognized, and U.S. territories or possessions. At the same time, it restricts foreign participation at the applicant level: non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, and non-domestic components of U.S. organizations are not eligible. However, “foreign components” are allowed as defined in the NIH Grants Policy Statement, which generally means a U.S. applicant may include certain elements of the project occurring outside the U.S. if they meet NIH’s definition and are justified, even though a foreign organization cannot be the applicant.
From an administrative standpoint, this is a discretionary NIH opportunity using the cooperative agreement funding instrument. The activity category is listed under education and health, and the CFDA/assistance listing numbers provided are 93.213 and 93.361. The original closing date shown in the source data is 2023-09-13. The award ceiling shown is $500,000, indicating an upper bound for the budget level under the announcement as presented in the source excerpt. The announcement is positioned around “expected awards,” but the provided text does not specify a numeric count, suggesting prospective applicants would need to consult the full NOFO for details such as the number of awards, project period limits, UG3 versus UH3 budget expectations, and required milestones and review criteria.
Overall, this NOFO is designed for teams that can partner effectively with large health care systems serving military and veteran communities and that are prepared to run pragmatic, implementation-aware clinical trials of nonpharmacologic pain care. The PMC framework and Coordinating Center are central to the model, with the goal of producing findings that are not only scientifically sound but also operationally realistic and directly useful for policy and practice across the VA, DoD, and related health care environments.Apply for RFA AT 24 004
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "NIH-DoD-VA Pain Management Collaboratory ? Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.361.
- This funding opportunity was created on 2023-07-20.
- Applicants must submit their applications by 2023-09-13. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the NIH-DoD-VA Pain Management Collaboratory (PMC) funding opportunity (RFA AT 24 004)?
This opportunity supports phased UG3/UH3 cooperative agreement projects focused on testing real-world, nonpharmacologic approaches to pain management for U.S. veterans, active-duty military personnel, and their families. Projects are expected to be embedded in health care systems and designed to produce actionable evidence about how non-drug pain care strategies work in routine clinical environments and how they can be adopted, delivered, and sustained at scale.
What is the main goal of projects funded through this announcement?
The central aim is to run efficient, large-scale pragmatic clinical trials and/or implementation science demonstration projects embedded in health care systems. The emphasis is on practical, real-world evaluation rather than tightly controlled laboratory-style conditions, with the intention that results are directly relevant to large health systems such as the VA and DoD.
Is a clinical trial required?
Yes. A clinical trial is required under this announcement, and the focus is specifically on demonstrating nonpharmacologic pain care strategies in real clinical environments.
What types of interventions are in scope?
The scientific scope emphasizes nonpharmacologic (non-drug) pain management approaches that can be delivered in routine practice and evaluated at scale. The provided summary does not list specific interventions, but it signals interest in evidence-based, non-drug strategies suitable for pragmatic testing in health care systems.
Are comorbid or co-occurring conditions relevant to proposed projects?
Yes. The opportunity notes that pain in veteran and military populations often occurs alongside other common comorbid conditions. This leaves room for projects that address pain alongside issues such as behavioral health concerns, sleep problems, physical function limitations, or other chronic conditions, including integrated care models designed for more complex patient needs.
What does it mean that studies should be "pragmatic" and "embedded in health care systems"?
It means projects are expected to reflect routine care settings and practical constraints. Rather than operating like tightly controlled experiments, studies should work within the realities of clinical workflows, staffing, operational priorities, and real-world data sources commonly used in health systems.
What is the UG3/UH3 phased structure?
The UG3/UH3 model is a two-phase, milestone-driven approach. The UG3 phase generally functions as a planning and startup period, while the UH3 phase is the larger execution period when the pragmatic trial and/or implementation study is carried out across health system settings.
What typically happens during the UG3 phase?
Based on the summary provided, the UG3 phase typically includes finalizing protocols, building site readiness, completing key regulatory and operational steps, and demonstrating feasibility benchmarks or milestones needed to support launch of the larger study.
What triggers the transition from UG3 to UH3?
Transition is milestone-driven. If the UG3 milestones are met, the project transitions to the UH3 phase, where the larger implementation and execution activities take place.
What typically happens during the UH3 phase?
The UH3 phase is the main implementation and execution period. This is when the pragmatic clinical trial and/or implementation science demonstration project is carried out across health system settings.
What is a "cooperative agreement," and how does it affect the project?
This opportunity uses a cooperative agreement funding instrument, which means NIH expects substantial scientific and programmatic involvement during the life of the award. The summary indicates this can include coordinated oversight, collaboration on common methods and standards, and active engagement with the broader collaboratory infrastructure.
Do applicants have to work within the Pain Management Collaboratory (PMC) infrastructure?
Yes. A defining feature of this opportunity is that projects must operate within the infrastructure of the NIH-DoD-VA Pain Management Collaboratory.
What is the role of the PMC Coordinating Center?
The PMC Coordinating Center is designed to provide national leadership and hands-on technical expertise for health care system-focused research. The summary indicates awardees can expect support and coordination around common pragmatic-trial challenges such as multi-site operations, workflow alignment with clinical care, use of real-world data sources (including electronic health records), standardizing outcomes where appropriate, and managing implementation challenges.
What kinds of challenges does the collaboratory aim to help with?
The summary highlights challenges typical of pragmatic trials, including working across multiple health care sites, aligning research activities with clinical operations and workflows, dealing with real-world data sources (like electronic health records), standardizing outcomes where appropriate, and addressing implementation barriers such as clinician uptake, fidelity, adaptation, and sustainability.
Who is the intended patient population?
Projects are intended to focus on U.S. veterans, active-duty military personnel, and their families.
What organizations are eligible to apply?
Eligibility is broad. The summary lists eligible applicants including state, county, and local governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; public and private institutions of higher education; federally recognized tribal governments; tribal organizations other than federally recognized governments; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses.
Are minority-serving institutions and community-based organizations included in eligible applicant categories?
Yes. The summary explicitly calls out additional eligible categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, TCCUs, faith-based or community-based organizations, regional organizations, eligible federal agencies, tribal governments other than federally recognized, and U.S. territories or possessions.
Can a non-U.S. (foreign) organization apply as the applicant?
No. The summary states that non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply.
Can a U.S. organization include a non-domestic component in its project?
No, non-domestic components of U.S. organizations are stated as not eligible. However, the summary also notes that "foreign components" are allowed as defined in the NIH Grants Policy Statement, meaning a U.S. applicant may include certain justified elements occurring outside the U.S. if they meet NIH's definition of a foreign component.
What is the funding instrument and federal assistance context for this opportunity?
This is a discretionary NIH opportunity using the cooperative agreement funding instrument. The activity category is listed under education and health, and the CFDA/assistance listing numbers provided are 93.213 and 93.361.
What is the award ceiling mentioned in the summary?
The award ceiling shown in the provided source excerpt is $500,000, indicating an upper bound for the budget level under the announcement as presented.
How many awards will be made?
The provided text references "expected awards" but does not specify a numeric count. The summary indicates applicants would need to consult the full NOFO for details such as number of awards.
What is the closing date listed in the source data?
The original closing date shown in the source data is 2023-09-13.
What details are not specified in the provided summary that applicants may need to confirm elsewhere?
The summary notes that key details are not provided here, including the number of awards, project period limits, UG3 versus UH3 budget expectations, required milestones, and review criteria. These items are indicated as needing confirmation in the full NOFO.
What types of study designs are encouraged?
The summary emphasizes large-scale pragmatic clinical trials and/or implementation science demonstration projects embedded in health care systems, with an explicit requirement for a clinical trial and a focus on real-world delivery, adoption, and sustainability.
How does this opportunity aim to make results useful for VA and DoD health systems?
By embedding studies in real care settings and leveraging PMC Coordinating Center support to address operational challenges (multi-site coordination, workflow integration, real-world data use, and implementation barriers), the program aims to reduce duplication of effort and increase the likelihood that findings are actionable for large health systems like the VA and DoD.
Browse more opportunities from the same category: Education, Health
Next opportunity: Cooperative Agreement for CESU-affiliated Partner with Great Lakes Northern Forest Cooperative Ecosystem Studies Unit
Previous opportunity: Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AT 24 004
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AT 24 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) Apply for RFA DA 25 014 Funding Number: RFA DA 25 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) Apply for PAR 23 246 Funding Number: PAR 23 246 Agency: National Institutes of Health Category: Education, Health Funding Amount: $475,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional) Apply for RFA DA 25 020 Funding Number: RFA DA 25 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) Apply for RFA DA 25 019 Funding Number: RFA DA 25 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing HIV in highest risk sexual and gender minorities (R34 Clinical Trial Required) Apply for RFA DA 25 002 Funding Number: RFA DA 25 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Addressing HIV in Highest Risk Sexual and Gender Minorities (R01 Clinical Trial Optional) Apply for RFA DA 25 001 Funding Number: RFA DA 25 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) Apply for PAR 23 254 Funding Number: PAR 23 254 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) Apply for PAR 23 255 Funding Number: PAR 23 255 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) Apply for PAR 23 245 Funding Number: PAR 23 245 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) Apply for PAR 23 259 Funding Number: PAR 23 259 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 23 243 Funding Number: PAR 23 243 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 23 242 Funding Number: PAR 23 242 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) Apply for PAR 23 264 Funding Number: PAR 23 264 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) Apply for PAR 23 273 Funding Number: PAR 23 273 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) Apply for PAR 23 244 Funding Number: PAR 23 244 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required) Apply for PAR 23 270 Funding Number: PAR 23 270 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) Apply for PAR 23 253 Funding Number: PAR 23 253 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) Apply for PAR 23 281 Funding Number: PAR 23 281 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) Apply for RFA CA 23 042 Funding Number: RFA CA 23 042 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional) Apply for RFA DA 25 018 Funding Number: RFA DA 25 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AT 24 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.